ARS Pharmaceuticals(SPRY) - 2024 Q3 - Quarterly Results

Exhibit 99.1 ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates Commercial launch of neffy® (epinephrine nasal spray) underway in the United States Supplemental NDA for neffy® 1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025 Exclusive license agreement with ALK-Abelló to commercialize neffy® in Europe, Canada and certain other geographies; ARS Pharma to receive $145 million in upfront payment with total deal consideration of up to $ ...